Permanent pacing after cardiac transplantation

Christopher D Scott, Janet M McComb, John H Dark, Rodney S Bexton

Abstract

Objective—To determine the need for long-term pacing and optimum mode of pacing in cardiac transplant recipients.

Design—(a) A retrospective review of patient records. (b) A prospective study of pacemaker use by 24 hour ambulatory electrocardiography before and after reprogramming to minimise use of pacemakers.

Setting—Outpatient clinic, supra-regional cardiopulmonary transplant unit.

Patients—All 21 patients at this centre who had received permanent pacemakers after cardiac transplantation. 18 of 19 survivors completed the prospective part of the study.

Main outcome measure—The presence of pacing during a 24 hour ambulatory electrocardiographic recording (programming: 50 beats/min, rate sensor inactivated).

Results—21 of 191 (11%) recipients surviving one month or more received permanent pacemakers. The indication was sinus node dysfunction in 13 (62%) and atrioventricular (AV) block in eight (38%). Patients who paced on follow up 12 lead electrocardiograms declined from 38% at three months to 10% at three years after transplantation. After programming to 50 beats/min only five of 18 (28%) patients paced during a 24 hour ambulatory recording. Four of 11 (36%) recipients who received pacemakers for sinus node dysfunction paced compared with one of seven patients (14%) paced for AV block. No patient who had a pacemaker before the 16th day after operation continued to pace whereas five of nine implanted later were used long-term.

Conclusion—Only five of 18 (28%) patients with pacemakers continued to pace long-term. Continued pacing was more common in those with persistent sinus node dysfunction after the second week after operation but the need for long-term pacing was not predictable.

(Please note: The usual resting heart rate after transplantation has been shown to be about 100 beats/min. This is due to the absence of autonomic innervation and reflects the dominance of vagal tone in the normal heart. It compares closely with studies of the intrinsic heart rate in pharmacologically denervated hearts. In the first few weeks after transplantation sinus or junctional bradycardia occur in more than 50% of recipients. Donor sinus node dysfunction is the most common cause of bradyarrhythmia, although atrioventricular block is responsible in some patients. These early bradyarrhythmias are usually controlled by isoprenaline infusion or temporary epicardial pacing. In some patients bradycardia persists and permanent pacing may be needed. Some authors have recently advocated complex modes of pacing in transplant patients who require permanent pacemakers. It was our impression, however, that permanent pacemakers are often used for a short period after transplantation and complex pacing systems might be unnecessary. This study was therefore undertaken to assess the frequency and predictability of long-term pacing requirements in patients who had received permanent pacemakers after transplantation.

Patients and methods

Between May 1985 and March 1992, 218 adults underwent orthotopic heart transplantation at this centre and 191 survived at least one month. The operative procedure was as described by Lower et al. Temporary epicardial atrial and ventricular pacing wires were placed at the time of operation in each patient and were removed around day 21 after operation.

In the early stages of our transplant programme VVI pacemakers were implanted between days 8 and 21 on a prophylactic basis when the resting heart rate was below 70 beats/min. Subsequently physiological and rate responsive systems were used as it was thought that these would improve exercise tolerance. The programmed rates were chosen to mimic heart rates achieved by other transplant patients without sinus or atrioventricular node dysfunction. A further review of our pacing policy was undertaken after an earlier study. Thereafter pacemakers were only implanted for symptomatic bradyarrhythmias that persisted after the end of the third postoperative week.)
RETROSPECTIVE REVIEW
The clinical records of all patients with permanent pacemakers were examined. The original indication for pacing, the implantation time, pacemaker type, and programming were noted. Treatment with cardioactive drugs, including preoperative amiodarone was recorded. The ischaemic time, donor age, and episodes of rejection were recorded for all transplant recipients. Complications related to pacemakers were noted. Resting 12-lead electrocardiograms taken at three monthly intervals during routine follow up were examined.

PROSPECTIVE STUDY
A 24 hour ambulatory electrocardiogram was performed on 18 of 19 surviving patients. In 16 patients a recording was made with the variables programmed at the time of implantation. In those patients in whom pacemaker activity was detected during the initial recording the pacemaker was reprogrammed to 50 beats/min with the rate sensor inactivated if present. The 24 hour ambulatory electrocardiogram was then repeated. Two patients had their pacemaker reprogrammed in this way to minimise its use before the initial recording.

STATISTICAL ANALYSIS
Statistical analyses were performed with Student's \( t \) test or Mann-Whitney U test. Results are expressed as mean (SD).

Results
RETROSPECTIVE STUDY
The table summarises the results. Of 191 adult heart transplant recipients surviving at least one month, 21 received permanent pacemakers. For 13 patients (62%) the indication for pacing was sinus node dysfunction, manifest as sinus bradycardia in 10 cases with rates of between 30 and 60 beats/min. The other three patients in this group had sinus arrest with nodal escape rhythm. Eight patients (38%) had pacemakers because of atrioventricular block. Six of these had second or third degree block and two had atrial flutter with variable block.

The mean interval between transplantation and permanent pacing was 19.4 days (range 90 to 90 days). Only one pacemaker was implanted after the first postoperative month. This patient had no early bradyarrhythmias. There was evidence of the bradycardia-tachycardia syndrome on a 24 hour ambulatory recording. This patient died four months after transplantation from infection and renal failure and could not therefore be included in the prospective part of the study. Four patients who had taken amiodarone before transplantation, each at a dose of 200 mg daily, for between one and 36 months. Isoprenaline was used in all subjects but only in the immediate postoperative period. No other cardioactive drugs were prescribed.

Ventricular pacemakers were implanted in 15 patients (eight rate responsive), atrial pacemakers in three (all rate responsive) and dual chamber in three (two rate responsive). The VVI pacemakers were programmed to 70 beats/min, the DDD to 90 beats/min. The rate responsive pacemakers were all activity sensing units and were programmed to a minimum rate of 80 beats/min and a maximum rate of 130 beats/min. There was no difference between the operative ischaemic time in those patients who subsequently required permanent pacemakers and those who did not (169 (40) min, \( n = 21 \) vs 169 (46) min, \( n = 170; p = 0.99 \) or between the donor ages (31.9 (9.5) vs 29.6 (9.3); \( p = 0.34 \)). The patients with pacemakers had a mean of 0.41 episodes of rejection (moderate, Billingham classification*) in the first month

<table>
<thead>
<tr>
<th>Results</th>
<th>Implantation day after operation</th>
<th>Months after operation</th>
<th>Tape 1</th>
<th>Tape 2</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Mode</td>
<td>Indication</td>
<td>3</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>1</td>
<td>VVI</td>
<td>SNR</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>VVI</td>
<td>SNR</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>VVI</td>
<td>AVB</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>VVI</td>
<td>AVB</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>VVI</td>
<td>AVB</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>DDD</td>
<td>SNR</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>VVI</td>
<td>AVB</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>VVI</td>
<td>SNR</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>VVI</td>
<td>AVB</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>VVIR</td>
<td>AVB</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>11</td>
<td>VVIR</td>
<td>AVB</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>12</td>
<td>VVIR</td>
<td>SNR</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>13</td>
<td>DDDDR</td>
<td>SNR</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>14</td>
<td>VVIR</td>
<td>SNR</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>15</td>
<td>VVIR</td>
<td>AVB</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16</td>
<td>VVIR</td>
<td>AVB</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>17</td>
<td>VVIR</td>
<td>AVB</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>AAIR</td>
<td>SNR</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>19</td>
<td>AAIR</td>
<td>SNR</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>20</td>
<td>DDDDR</td>
<td>AVB</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>21</td>
<td>AAIR</td>
<td>SNR</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

ECG, electrocardiogram indicating pacing; SNR, sinus node dysfunction; AVB, +, electrocardiographic evidence of pacing; -, electrocardiographic atrioventricular block; AVNRT, AV node reentrant tachycardia; evidence of no pacing; tape 1, 1st ambulatory electrocardiogram; tape 2, 2nd ambulatory electrocardiogram after reprogramming.
after operation compared with 0.32 episodes for other transplant recipients. This difference was not statistically significant (p = 0.18).

The frequency of pacing on resting 12 lead electrocardiograms declined progressively with time after transplantation from 8/20 (40%) at three months to 1/10 (10%) at 36 months (figure).

There were two episodes of lead displacement during 305 endomyocardial biopsy procedures with a ventricular lead in place. On both occasions the pacemaker had been implanted within the preceding 14 days and both leads were repositioned without incident. No atrial leads were displaced during 73 procedures with atrial leads in situ.

PROSPECTIVE STUDY

During the single 24 hour ambulatory electrocardiographic recording before reprogramming 12 of 18 patients paced intermittently. The rest were not pacing at all. The presence of any pacing was clearly related to the programming of the pacemaker implanted. Only one of five patients with a simple VVI device paced whereas 10 of 13 rate responsive pacemakers were used at some stage, often at rates of greater than 100 beats/min.

After reprogramming only five patients continued to be paced on a further single 24 hour ambulatory electrocardiographic recording. Two of these used their pacemaker only at night. One of the patients with a rate responsive pacemaker who paced intermittently on the initial recording was unable to tolerate inactivation of the rate sensor. The original indication in this patient was sinus node dysfunction and the underlying rhythm was sinus at 60 beats/min. Informal exercise testing produced no increase in heart rate and the patient experienced extreme fatigue and presyncope. The pacemaker was therefore programmed to 50–130 beats/min VVIR. Ambulatory monitoring showed continued intermittent pacing. No other patient reported any adverse effects from reprogramming.

After reprogramming one of seven (14%) subjects paced for atrioventricular block was pacing whereas 4 of 11 (36%) with sinus node dysfunction continued to pace.

Discussion

LIMITATIONS OF THE STUDY

The patients included in this study were identified retrospectively by the implantation of permanent pacemakers. Other patients with the rhythm disorders discussed who did not receive permanent pacemakers were therefore excluded. Although 12 lead electrocardiograms were available for all patients at the specified times after transplantation the ambulatory recordings were performed at variable times between three and 65 months. Single 24 hour ambulatory electrocardiograms provide insufficient data from which to be certain that the pacemakers are no longer required. Miyamoto et al. however removed an infected pacemaker in one of their patients after 24 hours of ambulatory monitoring showed that there had been no pacing.\(^4\) Our data and previous electrophysiological studies, suggest improvements in sinus node function with time, and some support to the conclusion that the pacemakers were no longer needed. Exercise tolerance was not formally assessed. We cannot therefore deny that some benefit results from pacing in patients who have no absolute requirement.

INDICATIONS FOR PERMANENT PACING

Sinus node dysfunction

Sinus node dysfunction after transplantation has been widely reported and studied by electrophysiology.\(^7\)\(^8\)\(^16\) The incidence varies from 50%\(^a\) early after transplantation (four to 24 days) to 29%\(^a\)\(^16\) in long-term survivors (four to 14 months).

The natural history of sinus node dysfunction during the first year after transplantation has not been described. It is clearly of importance when attempting to assess the need for permanent pacing in these patients. Heinz et al. reported that donor sinus arrest with or without junctional escape rhythm was predictive of persistent sinus node dysfunction,\(^7\) but electrophysiological indices were unhelpful.

Our overall implantation rate of 11% compares with rates of between 4%\(^a\) and 24%\(^a\)\(^7\) reported by other centres. A report by Mackintosh et al. published three years before the start of the transplant programme at this centre raised considerable concern about the prognosis in recipients with sinus node dysfunction.\(^8\) Four of five such patients died within four months of transplantation compared with none of five other patients studied. Only one of these deaths was shown to be due to bradycardia but as a result of this study, a low threshold for implanting permanent pacemakers was adopted at this and other centres.\(^9\) In two large series the indication for pacing in 35%\(^a\) and 61%\(^a\) of subjects was symptom free bradarrhythmias including sinus bradycardia.

The aetiology of persistent sinus node dysfunction after transplantation is unknown. Some authors have reported an association with prolonged operative ischaemic time\(^4\) but we and others\(^a\) have not confirmed these findings. Heinz and colleagues found an asso-
cation between transient but not persistent sinus dysfunction and prolonged ischaemic time. DiBiase et al linked abnormalities of the sinus node artery with sinus dysfunction.

**Atrioventricular block**

There are no published data on the frequency and natural history of atrioventricular block after transplantation. Although it was common in one series, in most it is much less common than sinus node dysfunction. Bexton et al found no evidence of atrioventricular block during electrophysiological studies in 14 patients at between four and 14 months after transplantation. Miyamoto et al described a slow ventricular response to atrial fibrillation and flutter in 1% (4/401) of transplant recipients. This resolved within 20 days and permanent pacing was not required. In the series published by DiBiase et al 10% of pacemakers were implanted for various degrees of atrioventricular block compared with 58% in our series. Our limited data from 12 lead electrocardiograms suggest that atrioventricular block after transplantation usually resolves within three to six months.

**Timing of Pacing**

In this study no patient who received a pacemaker before day 15 after operation continued to need a pacemaker long-term. Some authors have advocated pacing at between seven and 10 days after transplantation. This policy, however, may lead to unnecessary implantations particularly in patients with sinus node dysfunction that may continue to resolve throughout the first month. If clinical or electrophysiological variables (such as those suggested by Heinz et al) could be confirmed as reliable indicators of subsequent sinus node function then the optimum timing of pacemaker implantation would be more evident. Successful pharmacological treatment of these bradyarrhythmias with terbutaline or theophylline has been reported and would be particularly suitable if the problem was known to be temporary.

In the absence of such clear indicators the optimum timing of pacing must reflect a compromise between the advantages of early pacemaker implantation (increased mobility and earlier hospital discharge) and the risks of an invasive procedure in an immunocompromised patient. Epicardial pacing wires are usually removed on day 21 after operation at this centre. Unless other complications delay discharge a decision regarding permanent pacing is usually made at this point.

**The Need for Long-Term Pacing**

In this study five of 18 (28%) pacemaker recipients studied by ambulatory monitoring paced long-term while programmed to 50 beats min. The reported frequency of long-term pacing in transplant recipients varies considerably. In several series between 57% and 100% of recipients with pacemakers required long-term pacing but the programming details are not clearly described and ambulatory monitoring was not used in all of these studies.

**Late Implantation Pacemaker**

One of 21 pacemakers in our series was implanted after the first postoperative month. There are several reports of late bradyarrhythmias requiring permanent pacing, although the incidence is low compared with the immediate period after operation. Both sinus dysfunction and atrioventricular block have been described and accelerated graft coronary disease has been implicated in some cases. The paroxysmal nature of the bradyarrhythmias in our patient and the unpredictability in the onset of these arrhythmias also suggests a different aetiology from early bradyarrhythmias.

**MODE OF PACING**

The optimum mode of pacing in recipients of cardiac transplants is controversial. Physiological pacing is advocated by some authors10-12 and its advantages in non-transplant patients who need long-term pacing are clearly established. The haemodynamic benefits of atrial pacing in transplant recipients have been confirmed despite abnormal atrial morphology, characteristic of the transplanted heart. Many transplant recipients, however, may require relatively short-term pacing. For this reason and because of concern about the subsequent development of atrioventricular block some large centres advocate ventricular pacing in all cases.

In patients receiving atrial pacemakers the integrity of the atrioventricular conduction system is routinely tested by incremental atrial pacing and measurement of the Wenckebach point. There is no evidence to support concerns about the subsequent development of atrioventricular block in these patients.

In general the prescription of a rate adaptive pacemaker should be based on observed chronotropic incompetence. The chronotropic response to exercise is abnormal in all transplant recipients because of autonomic denervation. The resting heart rate is high but there is a delayed and blunted response of heart rate to exercise. There is, however, no evidence that rate adaptive pacing can improve on the chronotropic response of the normal sinus node after transplantation. Although the theoretical benefits of a pacemaker atrium sensing system are clear, the high incidence of recipient sinus node dysfunction may limit the general applicability of this technique. It also remains to be shown whether there is a significant clinical advantage.

The need for long-term pacing in transplant recipients receiving pacemakers soon after transplantation is infrequent. Those with sinus node dysfunction are more likely to require long-term pacing than those with atrioventricular block.

There are, however, at present no clear
prognostic indicators of subsequent pacing requirements in those with persistent bradyarrhythmias after the third week. A pacing system suitable for long-term use should therefore be selected. We recommend that implantation is delayed until at least 21 days after transplantation and until the patient is otherwise ready for discharge from hospital in order to reduce the frequency of unnecessary implantations.

The mode of pacing should be selected on an individual basis. Although there is no specific evidence of the superiority of physiological or rate responsive pacing in transplant recipients, the advantages in other patients are clearly established. Physiological pacing should probably be used where possible and rate adaptive systems used for those patients with confirmed chronotropic incompetence.

2 Scott CD, McComb JM, Dark JH. Heart rate and late mortality in cardiac transplant recipients. Eur Heart J 1993; (in press).
14 Scott CD, Omar I, McComb JM, Dark JH, Bexton RS. Long term pacing in heart transplant recipients is usually unnecessary. PACE 1991;14:1792-6.